---
title: "The latest research findings support Harvard's discovery: Novo Nordisk's weight loss drug Ozempic is associated with rare visual loss"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/222302525.md"
description: "Recent research indicates that Novo Nordisk's weight loss drug Ozempic is associated with rare visual loss (NAION), with obese patients using the drug being diagnosed with NAION at more than twice the rate. Although the risk of the eye condition remains relatively low, patients should remain vigilant. Novo Nordisk's stock price once fell by more than 3.3%"
datetime: "2024-12-13T16:02:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/222302525.md)
  - [en](https://longbridge.com/en/news/222302525.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/222302525.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/222302525.md) | [繁體中文](https://longbridge.com/zh-HK/news/222302525.md)


# The latest research findings support Harvard's discovery: Novo Nordisk's weight loss drug Ozempic is associated with rare visual loss

Large-scale trial results indicate that Novo Nordisk's weight loss drug Ozempic is associated with rare visual loss, supporting earlier research findings from Harvard University this year. Obese patients using Ozempic are more than twice as likely to be diagnosed with NAION. NAION occurs when reduced blood flow damages the visual nerve. The risk of this eye condition remains low; patients should be vigilant. Novo Nordisk's stock price in Denmark once fell over 3.3%.

Risk Warning and Disclaimer

The market carries risks, and investments should be made cautiously. This article does not constitute personal investment advice and does not take into account the specific investment goals, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article align with their specific circumstances. Investment based on this is at one's own risk

### 相关股票

- [Novo Nordisk AS (NVO.US)](https://longbridge.com/zh-CN/quote/NVO.US.md)
- [Eli Lilly (LLY.US)](https://longbridge.com/zh-CN/quote/LLY.US.md)
- [NUODE (600110.CN)](https://longbridge.com/zh-CN/quote/600110.CN.md)
- [IB SETTLEMENT (00147.HK)](https://longbridge.com/zh-CN/quote/00147.HK.md)

## 相关资讯与研究

- [FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market](https://longbridge.com/zh-CN/news/281394441.md)
- [FACTBOX-Pricing and availability of Novo, Lilly's weight-loss drugs](https://longbridge.com/zh-CN/news/281413480.md)
- [Here's How Much $100 Invested In abrdn Physical Silver Shares ETF 10 Years Ago Would Be Worth Today](https://longbridge.com/zh-CN/news/281394387.md)
- [Destiny Tech100 Stock Rises After SpaceX IPO Rumors](https://longbridge.com/zh-CN/news/281415250.md)
- [BREAKINGVIEWS-SpaceX IPO will gauge market moxie more than depth](https://longbridge.com/zh-CN/news/281406751.md)